RECENT ANALYSIS
OIG Examines Reporting Delays and Data Gaps in CDC and SAMHSA Submissions for the National Drug Control Strategy
The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report examining the challenges faced by the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) in compiling and reporting performance data for the National Drug Control Strategy (NDCS). The report focuses on the agencies’ submissions… (Eisen, December 4, 2024) #Mental and Behavioral Health
OIG Audit Finds Gaps in Office of Civil Rights’ HIPAA Oversight
The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report evaluating the effectiveness of the Office for Civil Rights’ (OCR) HIPAA audit program. This audit was prompted by increasing concerns about cyberattacks on healthcare organizations and the protection of electronic protected health information (ePHI). The report assessed whether OCR’s audits, guidance, and enforcement… (Eisen, December 4, 2024) #Health Information Technology, #Privacy
Two Manufacturer Participants for Cell and Gene Therapy Access Model Announced
The Centers for Medicare and Medicaid Services (CMS) announced that two manufacturers of sickle cell disease treatments will participate in the Center for Medicaid and Medicaid Innovation (CMMI) Cell and Gene Therapy (CGT) Access Model. Additional details follow. Manufacturer Participants: CMS details that bluebird bio, Inc., which manufactures LYFGENIA™, and Vertex Pharmaceuticals, which manufacture CASGEVYTM, have entered into agreements with… (Slifer, December 4, 2024) #Demonstration Programs, #Drug Pricing, #Prescription Drugs